Interleukin-2-dextran complexAlternative Names: IL-2-dextran complex; IL-2-encapsulated dextran micropheres; OctoDEX™-IL-2; sustained release IL-2
Latest Information Update: 14 May 2008
At a glance
- Originator OctoPlus
- Class Adjuvants; Antineoplastics; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants; Interleukin 2 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 May 2008 Discontinued - Preclinical for Cancer in Netherlands (unspecified route)
- 18 Aug 2003 Preclinical trials in Cancer in Netherlands (unspecified route)